Forte Biosciences (FBRX) to Release Earnings on Thursday

Forte Biosciences (NASDAQ:FBRX) is expected to be releasing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Forte Biosciences to post earnings of ($0.8785) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 21, 2026 at 9:30 AM ET.

Forte Biosciences (NASDAQ:FBRX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.08). On average, analysts expect Forte Biosciences to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Forte Biosciences Stock Up 0.0%

Shares of Forte Biosciences stock opened at $76.82 on Tuesday. Forte Biosciences has a 12-month low of $9.91 and a 12-month high of $77.20. The stock has a market cap of $1.07 billion, a P/E ratio of -16.56 and a beta of 2.60. The business’s 50 day moving average is $38.47 and its 200-day moving average is $31.54.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Brookline Capital Markets downgraded shares of Forte Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 27th. Wall Street Zen cut shares of Forte Biosciences from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 25th. TD Cowen downgraded shares of Forte Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, July 27th. Barclays lowered shares of Forte Biosciences from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $74.00 to $77.00 in a research report on Tuesday, July 28th. Finally, Weiss Ratings downgraded shares of Forte Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $72.50.

Institutional Trading of Forte Biosciences

A number of hedge funds have recently added to or reduced their stakes in FBRX. Global Retirement Partners LLC acquired a new position in Forte Biosciences in the 4th quarter valued at approximately $27,000. Bank of America Corp DE grew its stake in shares of Forte Biosciences by 5,641.8% in the third quarter. Bank of America Corp DE now owns 3,158 shares of the company’s stock worth $47,000 after purchasing an additional 3,103 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of Forte Biosciences in the third quarter worth $161,000. Jane Street Group LLC acquired a new stake in Forte Biosciences in the fourth quarter valued at $228,000. Finally, Citadel Advisors LLC acquired a new stake in Forte Biosciences in the third quarter valued at $234,000. Institutional investors and hedge funds own 77.63% of the company’s stock.

About Forte Biosciences

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.